Which company does Ustekinumab injection come from?

The trade nameStelara is ustekinumab (Ustekinumab), a drug produced by Janssen Pharmaceuticals (Janssen Monoclonal antibody drugs developed by Pharmaceuticals for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, mainlytargetIL-12 and IL-23. Clinical trials have shown that subcutaneous ustekinumab is generally well tolerated. Most treatment-emergent adverse events were mild.

Ustekinumab is approved in the United States, Israel, Australia, and the European Union for the treatment of Crohn's disease, in the United States for the treatment of ulcerative colitis, and in the European Union for the treatment of patients who have failed to respond to conventional treatments. In clinical studies, ustekinumab was found to be ineffective against multiple sclerosis. Ustekinumab is administered by intravenous infusion or subcutaneous injection. The antibody targets subunits of human interleukin 12 and interleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory diseases.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.